QbDVision, a provider of a Digital CMC platform for pharmaceutical and biotechnology companies, has announced the appointment of Christoph Pistek as Vice President, Digital CMC Solutions. Pistek will help customers start their CMC transformation, taking them from their original business objective through to technology implementation.

Pistek joins from Takeda, where he led global innovation initiatives as VP and Head of Sustainability and Technology in Pharmaceutical Sciences. He brings over 20 years of experience across R&D, technical and supply operations, and business excellence, with a track record in digital and organizational transformation.

Commenting on the appointment, Yash Sabharwal, CEO and Co-founder of QbDVision, said: “Christoph has implemented Digital CMC at scale from inside a global pharma company. He understands why transformation stalls and how to move it forward, and our customers will benefit from that experience.”

Digital CMC brings therapies to patients faster by speeding up drug development and technology transfer, replacing manual, paper-based workflows with structured data and automation. It can also help address a broader range of unmet medical needs, including diseases that have historically attracted less investment.

“Too often, digital transformation in CMC is run as a technology project,” Pistek said. “The organizations that get real value start from the business objective and own the transformation at the highest level.”

He continues: “CMC depends on input from more functions than almost any other part of a drug developer, for example, research, manufacturing, quality, regulatory, and commercial. We frequently see organizations lose valuable time to repeated assessments and RFPs, while costs climb and the status quo is locked in. The real risk isn’t getting it wrong; it's doing nothing, and continuing to work within the constraints of slow, manual, unstructured processes.”